Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Mar 7:rs.3.rs-2625838.
doi: 10.21203/rs.3.rs-2625838/v1.

PAM-Flexible Genome Editing with an Engineered Chimeric Cas9

Affiliations

PAM-Flexible Genome Editing with an Engineered Chimeric Cas9

Sabrina Koseki et al. Res Sq. .

Update in

  • PAM-flexible genome editing with an engineered chimeric Cas9.
    Zhao L, Koseki SRT, Silverstein RA, Amrani N, Peng C, Kramme C, Savic N, Pacesa M, Rodríguez TC, Stan T, Tysinger E, Hong L, Yudistyra V, Ponnapati MR, Jacobson JM, Church GM, Jakimo N, Truant R, Jinek M, Kleinstiver BP, Sontheimer EJ, Chatterjee P. Zhao L, et al. Nat Commun. 2023 Oct 4;14(1):6175. doi: 10.1038/s41467-023-41829-y. Nat Commun. 2023. PMID: 37794046 Free PMC article.

Abstract

CRISPR enzymes require a defined protospacer adjacent motif (PAM) flanking a guide RNA-programmed target site, limiting their sequence accessibility for robust genome editing applications. In this study, we recombine the PAM-interacting domain of SpRY, a broad-targeting Cas9 possessing an NRN > NYN PAM preference, with the N-terminus of Sc++, a Cas9 with simultaneously broad, efficient, and accurate NNG editing capabilities, to generate a chimeric enzyme with highly flexible PAM preference: SpRYc. We demonstrate that SpRYc leverages properties of both enzymes to specifically edit diverse NNN PAMs and disease-related loci for potential therapeutic applications. In total, the unique approaches to generate SpRYc, coupled with its robust flexibility, highlight the power of integrative protein design for Cas9 engineering and motivate downstream editing applications that require precise genomic positioning.

PubMed Disclaimer

Conflict of interest statement

Additional Declarations: Yes there is potential Competing Interest. P.C. and J.M.J. are listed as inventors for US Patent Application entitled: “Applications of Recombined ScCas9 Enzymes for PAM-free DNA Modification.” B.P.K is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies. B.P.K. is a consultant for EcoR1 capital, and is a scientific advisor to Acrigen Biosciences, Life Edit Therapeutics, and Prime Medicine. B.P.K. has a financial interest in Prime Medicine, Inc., a company developing therapeutic CRISPR-Cas technologies for gene editing. B.P.K.’s interests were reviewed and are managed by MGH and MGB in accordance with their conflict-of-interest policies.

Competing Interests Statement

P.C. and J.M.J. are listed as inventors for US Patent Application entitled: “Applications of Recombined ScCas9 Enzymes for PAM-free DNA Modification.” B.P.K is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies. B.P.K. is a consultant for EcoR1 capital, and is a scientific advisor to Acrigen Biosciences, Life Edit Therapeutics, and Prime Medicine. B.P.K. has a financial interest in Prime Medicine, Inc., a company developing therapeutic CRISPR-Cas technologies for gene editing. B.P.K.’s interests were reviewed and are managed by MGH and MGB in accordance with their conflict-of-interest policies.

Figures

Figure 1.
Figure 1.. Engineering, Modeling, and PAM Characterization of SpRYc.
(A) Homology model of SpRYc generated in SWISS-MODEL from PDB 4UN3 and visualized in PyMol. Original domain coordinates are indicated in parentheses above while SpRYc coordinates are indicated below. PAM is indicated in yellow, loop in purple, Sc++ N-terminus in red, and SpRY PID in blue. (B) PAM enrichment for indicated dCas9 enzymes utilizing PAM-SCANR. Each dCas9 plasmid was electroporated in duplicates, subjected to FACS analysis, and gated for GFP expression based on a negative “No Cas9” control and a positive dSpCas9 control. All samples were performed in independent transformation replicates, and the PAMs of the GFP-positive cells were sequenced via Sanger sequencing. (C) PAM profiles of SpCas9, Sc++, SpRY, and SpRYc proteins as determined by HT-PAMDA. Rate constants corresponding to Cas cleavage activity are illustrated as log10 values and are the mean of cleavage reactions against two unique spacer sequences.
Figure 2.
Figure 2.. Broad, Efficient, and Specific Genome Editing Capabilities of SpRYc.
(A) Quantitative analysis of indel formation with indicated Cas9 variants. Indel frequencies were determined via batch analysis following PCR amplification of indicated genomic loci, in comparison to unedited controls for each gene target. All samples were performed in independent transfection replicates and the mean of the quantified indel formation values was calculated. (B) Quantitative analysis of A-to-G with indicated ABE8e variants. Base editing conversion rates were determined via BEEP following PCR amplification of indicated genomic loci, in comparison to unedited controls for each gene target. All samples were performed in independent transfection replicates and the mean of the quantified base editing formation values was calculated. (C) Off-targets as identified by GUIDE-seq genome-wide for SpCas9, Sc++, SpRY, and SpRYc each paired with two sgRNAs targeting either EMX1 or VEGFA. Only sites that harbored a sequence with ≤10 mismatches relative to the gRNA were considered potential off-target sites. (D) Efficiency heatmap of mismatch tolerance assay on genomic targets. Quantified indel frequencies are exhibited for each labeled single or double mismatch (number of bases 5’ upstream of the PAM) in the sgRNA sequence for the indicated Cas9 variant and indicated PAM sequence. All samples were performed in independent transfection replicates and the mean of the quantified indel formation values was calculated.
Figure 3.
Figure 3.. Potential applications and structural mechanisms of SpRYc.
(A) Targeting disease-associated loci with SpRYc. (i) Schematic of SpRYc RTT Experiment. Base editing conversion rates were determined via CRISPResso2 NGS analysis following PCR amplification of MECP2-integrated loci, in comparison to unedited controls for the C502T installed mutation. Samples were performed in independent nucleofection triplicates (n=3) and the mean of the quantified base editing formation values was calculated. (ii) SpRYc-BE4Max was nucleofected into TruHD cells alongside an sgRNA targeting the HTT repeat. Base editing conversion rate was determined via CRISPResso2 NGS analysis NGS following PCR amplification of indicated genomic loci, in comparison to an unedited control. The analogous Sanger sequencing trace is shown. Samples were performed in independent nucleofection triplicates (n=3) and the mean of the quantified base editing formation values was calculated. (B) Structural insights via homology modeling in SWISS-MODEL. (i) Interaction of the engineered Sc++ loop (purple) with the backbone of the target strand (TS) PAM region. The REC1 loop from wild type SpCas9 is indicated in green. (ii) Potential interaction of residue R1331 with the non-target strand (NTS) backbone. (iii) Multiple mutations within the PAM interaction loop allow for a more flexible PAM readout. (iv) The potential van der Waals interaction of W1145 with the ribose moieties of non-target strand residues could further stabilize the PAM interaction.

References

    1. Mojica F. J. M., Díez-Villaseñor C., García-Martínez J. & Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733–740 (2009). - PubMed
    1. Jinek M. et al. A programmable dual-rna-guided dna endonuclease in adaptive bacterial immunity. Science (New York, N.Y.) 337, 816–821 (2012). - PMC - PubMed
    1. Shah S. A., Erdmann S., Mojica F. J. M. & Garrett R. A. Protospacer recognition motifs. RNA Biology vol. 10 891–899 Preprint at 10.4161/rna.23764 (2013). - DOI - PMC - PubMed
    1. Sternberg S. H., Redding S., Jinek M., Greene E. C. & Doudna J. A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62–67 (2014). - PMC - PubMed
    1. Gong S., Yu H. H., Johnson K. A. & Taylor D. W. DNA unwinding is the primary determinant of CRISPR-cas9 activity. Cell Reports 22, 359–371 (2018). - PMC - PubMed

Publication types